TABLE OF CONTENTS
1 INTRODUCTION 60
1.1 OBJECTIVES OF THE STUDY 60
1.2 MARKET DEFINITION 60
1.3 OVERVIEW OF THE GLOBAL HIGH CONTENT SCREENING MARKET 60
1.4 LIMITATIONS 62
1.5 MARKETS COVERED 62
2 MARKET SEGMENTATION 66
2.1 MARKETS COVERED 66
2.2 GEOGRAPHICAL SCOPE 67
2.3 YEARS CONSIDERED FOR THE STUDY 68
2.4 CURRENCY AND PRICING 68
2.5 DBMR TRIPOD DATA VALIDATION MODEL 69
2.6 MULTIVARIATE MODELLING 72
2.7 PRODUCT TYPE LIFELINE CURVE 72
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 73
2.9 DBMR MARKET POSITION GRID 74
2.10 MARKET APPLICATION COVERAGE GRID 75
2.11 VENDOR SHARE ANALYSIS 76
2.12 SECONDARY SOURCES 77
2.13 ASSUMPTIONS 77
3 EXECUTIVE SUMMARY 78
4 PREMIUM INSIGHTS 80
4.1 PESTEL ANALYSIS 83
4.2 PORTER'S FIVE FORCES MODEL 84
5 GLOBAL HIGH CONTENT SCREENING MARKET: REGULATIONS 85
6 MARKET OVERVIEW, GLOBAL HIGH CONTENT SCREENING MARKET 87
6.1 DRIVERS 89
6.1.1 ADVANCEMENT IN IMAGING TECHNOLOGIES USED FOR HIGH CONTENT SCREENING 89
6.1.2 STRATEGIC INITIATIVES TAKEN BY MARKET PLAYERS 89
6.1.3 INCREASING RESEARCH ACTIVITIES ASSOCIATED WITH THE USAGE OF HIGH CONTENT SCREENING 90
6.1.4 INCREASING DRUG DISCOVERY AND DEVELOPMENT ACTIVITIES 91
6.2 RESTRAINTS 91
6.2.1 HIGH COST ASSOCIATED WITH INITIAL SETUP AND MAINTENANCE 91
6.2.2 COMPLEXITY ASSOCIATED WITH CELLULAR AND MOLECULAR SAMPLES 92
6.3 OPPORTUNITIES 93
6.3.1 GROWING NUMBER OF CONTRACT RESEARCH ORGANIZATIONS (CROS) PROVIDING HCS SERVICES 93
6.3.2 RISING INTEGRATION WITH ARTIFICIAL INTELLIGENCE AND MACHINE LEARNING IN DRUG DISCOVERY AND DEVELOPMENT 93
6.3.3 INCREASING GOVERNMENT INITIATIVE AND FUNDING IN R&D 94
6.4 CHALLENGES 94
6.4.1 LACK OF SKILLED AND CERTIFIED PROFESSIONALS TO OPERATE HCS 94
6.4.2 DATA SECURITY AND DATA MANAGEMENT PROBLEMS IN HCS 95
7 GLOBAL HIGH CONTENT SCREENING MARKET, BY PRODUCT TYPE 96
7.1 OVERVIEW 97
7.2 INSTRUMENTS 100
7.2.1 CELL IMAGING AND ANALYSIS SYSTEM 101
7.2.1.1 FIXED 101
7.2.1.2 MOBILE 101
7.2.2 HIGH-CONTENT AND SCREENING SYSTEM 101
7.2.2.1 FIXED 102
7.2.2.2 MOBILE 102
7.2.3 FLOW CYTOMETRY 102
7.2.4 INVITROGEN HCA ONSTAGE INCUBATOR 102
7.2.5 MICROPLATE MOVER 102
7.2.6 OTHERS 102
7.3 SOFTWARE 102
7.4 CONSUMABLES 103
7.4.1 REAGENTS & ASSAY KITS 104
7.4.2 MICROPLATES 104
7.4.3 OTHERS 104
7.5 ACCESSORIES 104
7.6 SERVICES 105
8 GLOBAL HIGH CONTENT SCREENING MARKET, BY APPLICATION 107
8.1 OVERVIEW 108
8.2 PRIMARY AND SECONDARY SCREENING 111
8.2.1 INSTRUMENTS 112
8.2.2 CONSUMABLES 112
8.2.3 ACCESSORIES 112
8.2.4 SERVICES 112
8.3 TARGET IDENTIFICATION AND VALIDATION 112
8.3.1 INSTRUMENTS 113
8.3.2 CONSUMABLES 113
8.3.3 ACCESSORIES 113
8.3.4 SERVICES 114
8.4 TOXICITY STUDIES 114
8.4.1 INSTRUMENTS 115
8.4.2 CONSUMABLES 115
8.4.3 ACCESSORIES 115
8.4.4 SERVICES 115
8.5 COMPOUND PROFILING 115
8.5.1 INSTRUMENTS 116
8.5.2 CONSUMABLES 116
8.5.3 ACCESSORIES 116
8.5.4 SERVICES 117
8.6 OTHER APPLICATIONS 117
9 GLOBAL HIGH CONTENT SCREENING MARKET, BY TECHNOLOGY 118
9.1 OVERVIEW 119
9.2 MICROSCOPY 122
9.3 FLOW CYTOMETRY 122
9.4 IMMUNOHISTOCHEMISTRY 123
9.5 MASS SPECTROMETRY 124
9.6 ELISA 125
9.7 WESTERN BLOTTING 126
9.8 OTHERS 126
9.8.1 3D CELL CULTURE MODEL 127
9.8.1.1 STEROIDS 128
9.8.1.2 ORGANOIDS 128
9.8.1.3 TISSUE ON A CHIP 128
9.8.2 EXTRACELLULAR MATRIX BASED SCAFFOLD 128
9.8.3 SYNTHETIC HYDROGEL AND SCAFFOLD 128
10 GLOBAL HIGH CONTENT SCREENING MARKET, BY END USER 129
10.1 OVERVIEW 130
10.2 PHARMACEUTICAL AND BIOTECHNOLOGY COMPANIES 133
10.2.1 INSTRUMENTS 133
10.2.2 CONSUMABLES 134
10.2.3 ACCESSORIES 134
10.2.4 SERVICES 134
10.3 CONTRACT RESEARCH ORGANIZATIONS 134
10.3.1 INSTRUMENTS 135
10.3.2 CONSUMABLES 135
10.3.3 ACCESSORIES 135
10.3.4 SERVICES 135
10.4 LABORATORIES 136
10.4.1 INSTRUMENTS 137
10.4.2 CONSUMABLES 137
10.4.3 ACCESSORIES 137
10.4.4 SERVICES 137
10.5 ACADEMIC AND GOVERNMENT INSTITUTES 137
10.5.1 INSTRUMENTS 138
10.5.2 CONSUMABLES 138
10.5.3 ACCESSORIES 138
10.5.4 SERVICES 138
10.6 OTHERS 139
11 GLOBAL HIGH CONTENT SCREENING MARKET, BY DISTRIBUTION CHANNEL 140
11.1 OVERVIEW 141
11.2 DIRECT TENDERS 144
11.3 RETAIL SALES 144
12 GLOBAL HIGH CONTENT SCREENING MARKET, BY REGION 146
12.1 OVERVIEW 147
12.2 NORTH AMERICA 152
12.2.1 U.S. 163
12.2.2 CANADA 170
12.2.3 MEXICO 177
12.3 EUROPE 184
12.3.1 GERMANY 196
12.3.2 FRANCE 203
12.3.3 U.K. 210
12.3.4 ITALY 217
12.3.5 SPAIN 224
12.3.6 RUSSIA 231
12.3.7 TURKEY 238
12.3.8 BELGIUM 245
12.3.9 DENMARK 252
12.3.10 NETHERLANDS 259
12.3.11 SWITZERLAND 266
12.3.12 SWEDEN 273
12.3.13 POLAND 280
12.3.14 NORWAY 287
12.3.15 FINLAND 294
12.3.16 REST OF EUROPE 301
12.4 ASIA-PACIFIC 302
12.4.1 JAPAN 314
12.4.2 CHINA 321
12.4.3 INDIA 328
12.4.4 SOUTH KOREA 335
12.4.5 AUSTRALIA 342
12.4.6 NEW ZEALAND 349
12.4.7 SINGAPORE 356
12.4.8 THAILAND 363
12.4.9 MALAYSIA 370
12.4.10 VIETNAM 377
12.4.11 TAIWAN 384
12.4.12 INDONESIA 391
12.4.13 PHILIPPINES 398
12.4.14 REST OF ASIA-PACIFIC 405
12.5 SOUTH AMERICA 406
12.5.1 BRAZIL 417
12.5.2 ARGENTINA 424
12.5.3 REST OF SOUTH AMERICA 431
12.6 MIDDLE EAST AND AFRICA 432
12.6.1 SOUTH AFRICA 443
12.6.2 SAUDI ARABIA 450
12.6.3 BAHRAIN 457
12.6.4 U.A.E 464
12.6.5 KUWAIT 471
12.6.6 OMAN 478
12.6.7 QATAR 485
12.6.8 EGYPT 492
12.6.9 ISRAEL 499
12.6.10 REST OF MIDDLE EAST AND AFRICA 506
13 GLOBAL HIGH CONTENT SCREENING MARKET, COMPANY LANDSCAPE 507
13.1 COMPANY SHARE ANALYSIS: GLOBAL 507
13.2 COMPANY SHARE ANALYSIS: NORTH AMERICA 508
13.3 COMPANY SHARE ANALYSIS: EUROPE 509
13.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC 510
14 GLOBAL CONTENT SCREENING MARKET, COMPANY PROFILES 511
14.1 THERMO FISHER SCIENTIFIC INC. (2022) 511
14.1.1 COMPANY SNAPSHOT 511
14.1.2 REVENUE ANALYSIS 511
14.1.3 COMPANY SHARE ANALYSIS 512
14.1.4 PRODUCT PORTFOLIO 512
14.1.5 RECENT DEVELOPMENT 512
14.2 BD 513
14.2.1 COMPANY SNAPSHOT 513
14.2.2 REVENUE ANALYSIS 513
14.2.3 COMPANY SHARE ANALYSIS 514
14.2.4 PRODUCT PORTFOLIO 514
14.2.5 RECENT DEVELOPMENTS 514
14.3 PERKINELMER INC. (2022) 515
14.3.1 COMPANY SNAPSHOT 515
14.3.2 REVENUE ANALYSIS 515
14.3.3 COMPANY SHARE ANALYSIS 516
14.3.4 PRODUCT PORTFOLIO 516
14.3.5 RECENT DEVELOPMENTS 517
14.4 YOKOGAWA ELECTRIC CORPORATION (2022) 518
14.4.1 COMPANY SNAPSHOT 518
14.4.2 REVENUE ANALYSIS 518
14.4.3 COMPANY SHARE ANALYSIS 519
14.4.4 PRODUCT PORTFOLIO 519
14.4.5 RECENT DEVELOPMENT 519
14.5 MOLECULAR DEVICES, LLC. (A SUBSIDIARY OF DANAHER CORPORATION) 520
14.5.1 COMPANY SNAPSHOT 520
14.5.2 REVENUE ANALYSIS 520
14.5.3 COMPANY SHARE ANALYSIS 521
14.5.4 PRODUCT PORTFOLIO 521
14.5.5 RECENT DEVELOPMENT 522
14.6 AGILENT TECHNOLOGIES, INC. (2022) 523
14.6.1 COMPANY SNAPSHOT 523
14.6.2 REVENUE ANALYSIS 523
14.6.3 PRODUCT PORTFOLIO 524
14.6.4 RECENT DEVELOPMENT 524
14.7 ALIGNED GENETICS, INC. (2022) 525
14.7.1 COMPANY SNAPSHOT 525
14.7.2 REVENUE ANALYSIS 525
14.7.3 PRODUCT PORTFOLIO 526
14.7.4 RECENT DEVELOPMENT 526
14.8 ARACELI BIOSCIENCES 527
14.8.1 COMPANY SNAPSHOT 527
14.8.2 PRODUCT PORTFOLIO 527
14.8.3 RECENT DEVELOPMENT 527
14.9 AXXAM S.P.A 528
14.9.1 COMPANY SNAPSHOT 528
14.9.2 PRODUCT PORTFOLIO 528
14.9.3 RECENT DEVELOPMENT 528
14.10 BIO-RAD LABORATORIES, INC. (2022) 529
14.10.1 COMPANY SNAPSHOT 529
14.10.2 REVENUE ANALYSIS 529
14.10.3 PRODUCT PORTFOLIO 530
14.10.4 RECENT DEVELOPMENTS 530
14.11 CARL ZEISS AG 531
14.11.1 COMPANY SNAPSHOT 531
14.11.2 REVENUE ANALYSIS 531
14.11.3 PRODUCT PORTFOLIO 532
14.11.4 RECENT DEVELOPMENT 532
14.12 CORNING INCORPORATED 533
14.12.1 COMPANY SNAPSHOT 533
14.12.2 REVENUE ANALYSIS 533
14.12.3 PRODUCT PORTFOLIO 534
14.12.4 RECENT DEVELOPMENT 534
14.13 DE NOVO SOFTWARE 535
14.13.1 COMPANY SNAPSHOT 535
14.13.2 PRODUCT PORTFOLIO 535
14.13.3 RECENT DEVELOPMENTS 535

Menu 2

Sed ut perspiciatis unde omnis iste natus error sit voluptatem accusantium doloremque laudantium, totam rem aperiam.